[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"facial-palsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:facial-palsy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,84,111,166,197,221,253,276],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100430528","eye-tracking-fp-a-pilot-study-of-the-quantitative-evaluation-of-the-attention-paid-to-faces-with-facial-palsy-by-the-eye-tracking-technology-100430528",false,"NCT04886245","Eye-Tracking FP \"A Pilot Study of the Quantitative Evaluation of the Attention Paid to Faces With Facial Palsy by the Eye-tracking Technology.","EyeTrackingFP","Inclusion Criteria:\n\n* for patient with facial paralysis:\n* Patient with peripheral facial palsy, irrespective of grade, whether or not previously treated\n* Patient providing written informed consent\n* Patient aged ≥ 18 years\n* Patient affiliated to a social security system\n* for Healthy voluntary subject :\n* Subject without major facial sequelae\n* Subject who provided written informed consent\n* Major subject ≥ 18 years old\n* Subject affiliated to a social security system\n\nExclusion Criteria:\n\n* for Patient with facial paralysis:\n* Patient with recent peripheral facial palsy whose total recovery is possible\n* Patient unable to provide written informed consent\n* Patient with difficulties to follow instructions and especially to stand in front of a computer screen\n* Minor patient \\\u003C18 years\n* Patient under guardianship or curators or judicial safeguard\n* for Healthy voluntary subject :\n* Subject with major facial sequelae\n* Subject not able to provide written informed consent\n* Subject presenting difficulties in following instructions and in particular in standing still in front of a computer screen\n* Minor subject \\\u003C 18 years old\n* Subject under guardianship or curators or judicial safeguard",true,"ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The facial palsy concerns between 15 and 40 people per 100000 inhabitants. They are of various etiologies such as infectious, tumoral, traumatic or idiopathic.\n\nIt has variable severities with sometimes heavy functional repercussions and different recovery potentials. The proposed palliative treatments are based on surgery, physiotherapy and botulinum toxin injections. However, when recovery is incomplete, acceptance is more difficult, with an impacted quality of life. In this context, patients' expectations and feelings about their care may become difficult for clinicians to apprehend.\n\nThe eye-tracking is widely used in the marketing field, but it also finds medical applications including head and neck lesions and facial palsy in particular. Published studies focus on the gaze of photographs, excluding any notion of dynamics and by the analysis of the gaze of outside observers, ignoring the patient's gaze.The main objective is to evaluate the attention paid to the facial side with abnormal facial movement by patients with facial paralysis compared to healthy volunteers.",[27,28],"Eye-tracking","Facial Palsy",[30,31,28],"facial mimics","eye-tracking","RECRUITING","2026-05-12",{"date":35,"type":36},"2026-05-13","ACTUAL",{"date":38,"type":36},"2021-05-06",{"date":40,"type":21},"2027-07",{"name":42,"class":43},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":44},"100632242","relationship-between-facial-palsy-and-psychological-distress-100632242","NCT07511140","Relationship Between Facial Palsy and Psychological Distress","Relationship Between Severity of Facial Nerve Dysfunction and Psychological Distress in Patients With Bell's Palsy","FNP-Psy","Inclusion Criteria:\n\n* Patients with unilateral idiopathic Bell's palsy confirmed by nerve conduction studies (NCS) will be included.\n* The age of patients ranged from 25 to 50 years.\n* The duration of Bell's palsy ranged from three months to two years.\n* Patients with a body mass index (BMI) less than 30 kg\u002Fm² will be included.\n* Only patients who were able to comprehend and complete questionnaires will be included in the study.\n\nExclusion Criteria:\n\n* History of recurrent facial palsy or bilateral facial nerve involvement.\n* Presence of other neurological disorders unrelated to facial palsy affecting the face (e.g., stroke, multiple sclerosis).\n* A current diagnosis of psychiatric illness prior to the onset of facial palsy.\n* Cognitive impairment preventing valid completion of assessments.\n* Sleep disorders.\n* Diabetes mellitus.","25 Years","50 Years",{"count":56,"type":21},85,"OBSERVATIONAL","The goal of this observational cross-sectional study is to investigate whether the severity of facial dysfunction is associated with psychological distress in patients with unilateral facial palsy.\n\nThe main questions it aims to answer are:\n\n* Is there a significant relationship between the degree of facial muscle dysfunction (as measured by Sunnybrook Facial Grading Scale and EMG parameters) and levels of anxiety and depression (as measured by HADS)?\n* Does reduced facial function correlate with lower self-esteem levels (as measured by the Arabic version of the Single-Item Self-Esteem Scale)?\n\nResearcher will assess and analyze the correlation between facial motor impairment and psychological outcomes to determine whether greater functional impairment is associated with increased psychological distress.\n\nParticipants will:\n\n* Undergo clinical assessment using the Sunnybrook Facial Grading Scale to evaluate facial nerve function\n* Receive electrophysiological evaluation using surface electromyography (sEMG) to measure muscle activity\n* Complete standardized questionnaires including the Hospital Anxiety and Depression Scale (HADS) and the Arabic Single-Item Self-Esteem Scale (A-SISE)",[28],[61,62,63,64,65,66,67,68,69,70,71,72,73],"Facial nerve palsy","Bell's palsy","facial dysfunction","psychological distress","anxiety","depression","self-esteem","Electromyography","EMG","surface electromyography (sEMG)","Sunnybrook Facial Grading System","Hospital Anxiety and Depression Scale (HADS)","Single-Item Self-Esteem Scale (SISE)","NOT_YET_RECRUITING","2026-04-04",{"date":77,"type":36},"2026-04-09",{"date":79,"type":21},"2026-04-15",{"date":81,"type":21},"2026-07-28",{"name":83,"class":43},"Cairo University",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":44},"100617975","effect-of-neuromuscular-electrical-stimulation-on-unilateral-central-facial-palsy-100617975","NCT07325604","Effect of Neuromuscular Electrical Stimulation on Unilateral Central Facial Palsy","Effect of Neuromuscular Electrical Stimulation on Unilaterial Central Facial Palsy: An Assesorblinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Central facial palsy\n* First time stroke\n* \\>=18 years\n* Able to provide written consent\n\nExclusion Criteria:\n\n* Not able to cooperate for mimical exercises\n* Contraindications for NMES\n* Admitted for three weeks assessment stay at the hospital",{"count":92,"type":21},130,[24],"Background Central facial palsy (CFP) is a common condition in stroke, with an estimated prevalence of 45%. CFP can lead to facial asymmetry, problems with mouth closure and food processing, bite marks on the cheek, social isolation, and reduced quality of life. CFP is seen as an important area of rehabilitation, and training is therefore often carried out to reduce the consequences of CFP. In a recent systematic review conducted by the principal investigator, the results showed that very few studies have been conducted that have investigated the effect of training for CFP, and there is currently no scientific evidence to support the effect of the various training interventions.\n\nObjective To investigate the effect of Neuromuscular electrical stimulation (NMES) on facial symmetry compared to usual practice, in participants with CFP as a result of stroke.\n\nHypothesis: Participants who receive training with NMES together with usual training for facial paralysis have greater improvement in facial symmetry than participants who only receive usual training for facial paralysis.\n\nTrial design Randomized controlled trial (RCT) with a nested pilot trial. A pilot trial\u002FRCT will be conducted in order to power calculation in an RCT. The protocol for the pilot trial and RCT will be the same, and participants from the pilot trial and their outcome data are thus expected to be included in the RCT.",[28,96],"Stroke",[98,99,100,96,101],"NMES","Central facial palsy","Multicenter RCT","Facial symmetry","2026-03-06",{"date":104,"type":36},"2026-03-09",{"date":106,"type":36},"2026-02-27",{"date":108,"type":21},"2030-12-15",{"name":110,"class":43},"University of Aarhus",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":16,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":120,"conditions":121,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100290335","genetic-studies-of-strabismus-congenital-cranial-dysinnervation-disorders-ccdds-and-their-associated-anomalies-100290335","NCT03059420","Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies","Inclusion Criteria:\n\n* The Engle Lab is very interested in enrolling individuals with congenital conditions related to eye movement, cranial nerve and brainstem-based dysfunction, often broadly referred to as congenital cranial dysinnervation disorders (CCDDs).\n\nExclusion Criteria:\n\n* Individuals with cranial nerve disorders associated with known disorders, such as Saethre-Chotzen associated with established genetic mutations, or acquired conditions including trauma, stroke, tumor or spinal cord injuries.","1 Day",{"count":119,"type":21},20000,"The purpose of this study is to identify genes associated with impaired development and function of the cranial nerves and brainstem, which may result in misalignment of the eyes (strabismus) and related conditions.",[122,123,124,125,126,127,128,129,130,28,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146],"Congenital Fibrosis of Extraocular Muscles","Duane Retraction Syndrome","Duane Radial Ray Syndrome","Mobius Syndrome","Brown Syndrome","Marcus Gunn Syndrome","Strabismus Congenital","Horizontal Gaze Palsy","Horizontal Gaze Palsy With Progressive Scoliosis","Facial Paresis, Hereditary, Congenital","Third Nerve Palsy","Fourth Nerve Palsy","Sixth Nerve Palsy","Synkinesis","Ocular Motility Disorders","Levator-Medial Rectus Synkinesis","Athabaskan Brainstem Dysgenesis","Tongue Paralysis","Ninth Nerve Disorder","Fifth Nerve Palsy","Seventh Nerve Palsy","Eleventh Nerve Disorder","Twelfth Nerve Disorder","Vagus Nerve Paralysis","Moebius Sequence",[148,149,150,151,152,153,154,155,156],"CFEOM (Congenital Fibrosis of Extraocular Muscles)","CCDD (Congenital Cranial Dysinnervation Disorders)","DRS (Duane Retraction Syndrome)","DRRS (Duane Radial Ray Syndrome)","Strabismus","MGJWS (Marcus Gunn Jaw Winking Syndrome)","HGP (Horizontal Gaze Palsy)","HGPPS (Horizontal Gaze Palsy with Progressive Scoliosis)","Moebius","2026-02-09",{"date":159,"type":36},"2026-02-11",{"date":161,"type":36},"2004-02-01",{"date":163,"type":21},"2030-01",{"name":165,"class":43},"Boston Children's Hospital",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":44},"100557759","safety-and-effectiveness-of-the-blinker-system-in-participants-with-facial-nerve-palsy-100557759","NCT06542289","Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy","Single-Arm, Multicenter Study to Evaluate the Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy","Paralysis","Inclusion Criteria:\n\n22 years of age or older\n\n* Unilateral facial palsy due to any of the following: Bell's palsy, Ramsay Hunt syndrome, malignant or benign tumor resection, Lyme disease, cerebrovascular accident (hemorrhagic or ischemic), or trauma\n* A deficit in eye closure during blinking, defined as a mean blink score ≤2.0 in the study eye on the scale by Mäkelä, et al, as graded by the investigator.\n* Willing and able to comply with the study procedures and follow-up\n* Willing and able to provide informed consent\n* English, Spanish, or Hebrew, Arabic -speaking\n* In a trial with the BlinkER System, the device produces blinks sufficient to cover the pupil in the study eye, defined as a mean grade ≥ 3.0 on the Mäkelä scale, as graded by the investigator.\n* Participant successfully completes BlinkER System training and certification\n\nExclusion Criteria:\n\n* Bilateral facial paralysis (for example Parkinson's Disease)\n* History of prior intervention that is providing closure of the eyelids (e.g., facial reanimation, complete tarsorrhaphy surgery, etc.)\n* Has an implanted eyelid weight in the study eyelid.\n* History of diabetic neuropathy, unstable cardiovascular disease, neurologic disease causing severe cognitive or motor impairment, severe immunological deficiency, or malignant diseases that are not in remission\n* Signs of corneal infection, severe ocular surface inflammation, or significant periorbital skin inflammation\u002Finfection\n* Suspected or diagnosed epilepsy.\n* Cancerous lesions in the area where the BlinkER system electrodes will be applied.\n* Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device\n* Cornea or iris abnormalities that preclude visualization of the pupil\n* Cranial nerve V palsy or neurotrophic keratitis\n* Synkinesis that results in eyelid closure\n* Known allergy to any of the patient-contacting materials of the BlinkeER electrode (i.e. polyethylene (PET) film tape or hydrogel)\n* Participants who are pregnant or nursing.\n* Participation in another ophthalmic clinical trial within one year prior to enrollment. Participant must also be willing to refrain from another ophthalmic study for the duration of the study.\n* Co-existing condition, either ocular or non-ocular that, in the judgement of the investigator could affect the safety or effectiveness of treatment or the compliance of the participant to the protocol.","22 Years","120 Years",{"count":177,"type":21},80,[24],"Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.",[181,182,183,28],"Bell's Palsy","Ramsay Hunt Syndrome","Lyme Disease",[185,186],"BlinkER System","BlinkER","2025-06-08",{"date":189,"type":36},"2025-06-10",{"date":191,"type":21},"2025-10-01",{"date":193,"type":21},"2026-11-30",{"name":195,"class":196},"Neurotrigger Ltd","INDUSTRY",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":44},"100483949","multimodal-quantified-analysis-of-facial-movements-comparison-between-pathological-and-control-subjects-100483949","NCT05581680","Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological and Control Subjects","Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological","AQ2MF","Inclusion Criteria:\n\n* Subjects with no known facial pathology (healthy volunteers) OR\n* Patients with peripheral facial palsy, irrespective of grade, whether or not previously treated\n* Subject with written informed consent\n* Subject over 18 years of age\n* Subject affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Subjects with severe skin disorders that do not allow the application of electrodes or photo reflective markers\n* Subjects with speech disorders making it impossible to pronounce the sounds \\[o\\] and \\[pu\\]\n* Subject unable to provide written informed consent\n* Subjects under guardianship, curators or safeguard of justice",{"count":206,"type":21},720,[24],"The facial palsy is a frequent disease with a lot of etiologies. It has variable severities with sometimes heavy functional repercussions and different recovery potentials. The proposed treatments are based on surgery, physiotherapy and botulinum toxin injections. However, when recovery is incomplete, acceptance is more difficult, with an impacted quality of life. Thanks to Motion Capture and Electromyography, a quantification of the facial mimicry is now possible with a great precision. In addition with the quantification of the facial mimicry, eye-tracking, wich is widely used in the marketing field, but it also finds medical applications including head and neck lesions and facial palsy in particular, will be used to evaluate the visio of the patients on their pathology in function of the movement quantification measured with MoCap and Electromyography. The aim of this research is to measure in a combined way the action potentials by sEMG and the amplitudes of displacement of the markers in motion capture, for movements determined in a population of patients presenting a facial pathology, in order to compare them with reference values obtained in healthy subjects. In a second step, the aim will be to study if there is a link between the way the patient looks at his pathology and the results of his management (treatment, rehabilitation) which will be quantitatively evaluated thanks to MoCap and sEMG.",[68,27,28],[30,211,212,31,28],"motion capture","electromyography","2025-05-22",{"date":215,"type":36},"2025-05-28",{"date":217,"type":36},"2022-10-12",{"date":219,"type":21},"2028-10",{"name":42,"class":43},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":252},"100345745","phase-4-evaluation-of-cortisone-treatment-in-children-with-acute-facial-nerve-palsy-100345745","NCT03781700","Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy","The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial","FACE","Inclusion Criteria:\n\n1. 1-17 years of age\n2. Acute peripheral unilateral facial nerve palsy\n3. Less than 72 hours since debut of symptoms\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. Head trauma \\\u003C1 month\n2. Central or bilateral facial nerve palsy\n3. Malformations in head and neck\n4. Conditions not compatible with cortisone treatment (arterial hypertension, diabetes mellitus, psychiatric disorder, active or latent tuberculosis, intolerance of lactose)\n5. Current or past oncological diagnosis\n6. Other serious medical conditions (meningitis, encephalitis, stroke)\n7. Acute otitis media\n8. Signs of herpes simplex or varicella zoster infection (vesicles in the ear region)\n9. Pregnancy or breastfeeding\n10. Use of any systemic or inhaled steroids within 2 weeks prior onset of symptoms\n11. Immunization with live vaccine 1 month prior onset of symptoms\n12. Requirement of live vaccine within 2 months from start of experimental treatment (prednisolone or placebo)\n13. Evaluation of primary endpoint at 12 months not feasible for any reason\n14. Previously included into the FACE study","1 Year","17 Years",{"count":232,"type":21},500,[234],"PHASE4","Acute facial nerve palsy occur in 10-20\u002F100 000 children\u002Fyear in Sweden. About 20 % of these children will have persistent symptoms with excessive tear secretion, drooling and social problems due to asymmetry in the face. Studies on cortisone treatment to adult patients with acute facial nerve palsy have shown beneficial effects, but no studies with strong quality have been performed in children.\n\nInvestigators will perform a double-blind randomized placebo-controlled multicenter trial on children with acute facial nerve palsy. Participants will be recruited consecutively at 9-12 study centers in Sweden during 2019-2020. Oral cortisone (prednisolone) 1 mg\u002Fkg x 1 in 10 days (or placebo) will be started on admission. Clinical data, including recovery will be followed-up until 12 months.\n\nThe primary outcome is defined as total recovery of the facial nerve palsy, measured with the House-Brackmann scale (grade 1) at 12-months follow-up.\n\nThe overall purpose is to assess the utility of cortisone treatment given to children with acute facial nerve palsy in this study. If the total recovery rate is significantly improved in the prednisolone group as compared to the placebo group, prednisolone treatment will be introduced in clinical practice for children with acute facial nerve palsy in order to reduce the risk of persistent symptoms.",[28,237,238,239],"Facial Nerve Diseases","Borrelia Infection of Central Nervous System","Bell Palsy",[241,242],"Children","Paediatric","2025-02-20",{"date":245,"type":36},"2025-02-21",{"date":247,"type":36},"2019-05-03",{"date":249,"type":21},"2026-12-31",{"name":251,"class":43},"Dalarna County Council, Sweden",15,{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":4},"100573128","stellate-ganglion-block-in-longstanding-facial-nerve-palsy-patients-100573128","NCT06742255","Stellate Ganglion Block in Longstanding Facial Nerve Palsy Patients","Inclusion Criteria:\n\n* facial nerve palsy patients\n\nExclusion Criteria:\n\n1. light of a recent myocardial infarction.\n2. anticoagulant use\n3. glucoma\n4. lateral nerve palsy\n5. emphysema\n6. cardiac conduction abnormalities\n7. active infection, flu, cold\n8. uncontrolled cough\n9. Fever\n10. Very high blood pressure or if you are on blood thinners.\n11. allergic reaction to local anesthetics\n12. Primary and secondary coagulopathy.",{"count":260,"type":21},34,"The goal of the present study is to verify the efficacy of stellate ganglion block (SGB) in the treatment of facial pain",[263,28,264],"Stellate Ganglion","Pain Management",[266,267],"Stellate gangliom","Facial palsy","2024-12-16",{"date":270,"type":36},"2024-12-19",{"date":272,"type":21},"2024-12-20",{"date":272,"type":21},{"name":275,"class":43},"Assiut University",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":290,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":44},"100557037","functional-recovery-from-facial-paralysis-100557037","NCT06532903","Functional Recovery From Facial Paralysis","Evaluation of Functional Recovery of Facial Paralysis in People With Different Kinesic Treatment Options.","Inclusion Criteria:\n\n* Patients with a medical referral that indicates as a diagnosis:\n* Peripheral facial paralysis\n* Bell's palsy\n* Frigori facial paralysis\n* Idiopathic facial paralysis, who have NOT received prior kinesic treatment.\n\nExclusion Criteria:\n\n* Patients with central facial paralysis (facial paralysis associated with stroke)\n* Patients with peripheral facial paralysis of more than 6 months' duration, will be excluded from the study.\n* Patients who present skin lesions that interfere with the application of electrical currents (open wounds, lacerations or burns)\n* Patients who attend with a medical prescription that advises against the use of electrostimulation in writing.",{"count":284,"type":21},50,[24],"This is a controlled, single-blind (hybrid) clinical investigation that aims to analyze the process of recovery of muscle function in people with peripheral facial paralysis who receive kinesthetic treatment with electrostimulation compared to those who receive treatment without electrostimulation, in the UNNE University Kinesiology Service, during the period 2023-2025, to promote early reintegration into their social activities of daily life.\n\nAn initial evaluation will be carried out, the movements that cause the requested gestures will be observed and recorded and recorded on a monitoring sheet and on video. The House Brackman and Sunnybrook scale will be used to measure functional outcomes. The initial and final evaluations will be external and blind. Patients will sign informed consent approved by Resolution No 04\u002F23 of the Health Sciences Research Bioethics Committee.\n\nThe following inclusion criteria will be taken into account: patients with a medical referral that indicates a diagnosis of peripheral facial paralysis, Bell's palsy, frigori facial paralysis, idiopathic facial paralysis, who have not received previous kinesic treatment. Patients with central facial paralysis (associated with stroke), with peripheral facial paralysis of more than 6 months of evolution, who present dermal lesions that interfere with the application of electrical currents (open wounds, lacerations or burns) will be excluded from the study. ) In addition, those patients who attend with a medical prescription that advises in writing against the use of electrostimulation will be excluded.",[288,28,289],"Peripheral Facial Paralysis","Synkineses",[291,292,293,294,295],"electrostimulation","peripheral facial paralysis","facial muscles","mime","selective muscle electrostimulation","2024-07-31",{"date":298,"type":36},"2024-08-01",{"date":300,"type":36},"2023-06-01",{"date":302,"type":21},"2025-12-31",{"name":304,"class":43},"Universidad Nacional del Nordeste, Argentina"]